Nuveen
ANIK icon

Nuveen’s Anika Therapeutics ANIK Stock Holding History

Nuveen’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Buy
156,538
+35,821
+30% +$531K ﹤0.01% 2510
2026
Q1 		$1.75M Buy
120,717
+67,515
+127% +$784K ﹤0.01% 2325
2025
Q4 		$511K Buy
53,202
+22,830
+75% +$219K ﹤0.01% 2860
2025
Q3 		$285K Hold
30,372
– – ﹤0.01% 3072
2025
Q2 		$321K Sell
30,372
-10,943
-26% -$138K ﹤0.01% 3023
2025
Q1 		$621K Hold
41,315
– – ﹤0.01% 2830
2024
Q4 		$680K Hold
41,315
– – ﹤0.01% 2876
2024
Q3 		$1.02M Sell
41,315
-58,761
-59% -$1.52M ﹤0.01% 2750
2024
Q2 		$2.53M Sell
100,076
-96,100
-49% -$2.49M ﹤0.01% 2269
2024
Q1 		$4.98M Sell
196,176
-69,300
-26% -$1.68M ﹤0.01% 1998
2023
Q4 		$6.02M Buy
265,476
+128,369
+94% +$2.66M ﹤0.01% 1876
2023
Q3 		$2.55M Buy
137,107
+22,455
+20% +$466K ﹤0.01% 2202
2023
Q2 		$2.98M Sell
114,652
-6,560
-5% -$176K ﹤0.01% 2168
2023
Q1 		$3.48M Buy
121,212
+51,420
+74% +$1.53M ﹤0.01% 2087
2022
Q4 		$2.07M Buy
69,792
+15,079
+28% +$429K ﹤0.01% 2376
2022
Q3 		$1.3M Sell
54,713
-852
-2% -$19.6K ﹤0.01% 2618
2022
Q2 		$1.24M Sell
55,565
-3,449
-6% -$76.9K ﹤0.01% 2691
2022
Q1 		$1.58M Buy
59,014
+528
+0.9% +$16.1K ﹤0.01% 2618
2021
Q4 		$2.16M Sell
58,486
-3,785
-6% -$152K ﹤0.01% 2536
2021
Q3 		$2.47M Sell
62,271
-29,680
-32% -$1.22M ﹤0.01% 2578
2021
Q2 		$3.98M Buy
91,951
+27,254
+42% +$1.16M ﹤0.01% 2356
2021
Q1 		$2.64M Sell
64,697
-915
-1% -$34.7K ﹤0.01% 2484
2020
Q4 		$2.97M Sell
65,612
-1,864
-3% -$70.7K ﹤0.01% 2314
2020
Q3 		$2.39M Buy
67,476
+4,761
+8% +$172K ﹤0.01% 2291
2020
Q2 		$2.37M Buy
62,715
+9,267
+17% +$305K ﹤0.01% 2268
2020
Q1 		$1.54M Sell
53,448
-97,303
-65% -$3.94M ﹤0.01% 2313
2019
Q4 		$7.82M Sell
150,751
-60,919
-29% -$3.54M ﹤0.01% 1737
2019
Q3 		$11.6M Buy
211,670
+155,339
+276% +$7.98M ﹤0.01% 1472
2019
Q2 		$2.29M Buy
+56,331
New +$2.05M ﹤0.01% 2371

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Nuveen's ANIK Position: Q2 2026 in Review

Nuveen increased its Anika Therapeutics (ANIK) stake by 30% in Q2 2026, buying an estimated $531K and bringing the position to 156,538 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2510.

Nuveen first reported a position in ANIK in Q2 2019 and has held it in 29 quarters since. The position peaked at $11.6M in Q3 2019. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Nuveen held 156,538 shares of Anika Therapeutics worth $2.29M as of Q2 2026.
  • Nuveen bought 35,821 Anika Therapeutics shares in Q2 2026, an estimated $531K.
  • Anika Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2510 holding.
  • Nuveen first reported a position in Anika Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Anika Therapeutics position peaked at $11.6M in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.